萬孚生物(300482.SZ):終止實施2024年限制性股票激勵計劃
格隆匯6月18日丨萬孚生物(300482.SZ)公佈,因公司經營所面臨的內外部環境與制定股權激勵計劃時相比發生了較大變化,導致公司預期經營情況與激勵方案考覈指標的設定存在偏差,繼續推進和實施激勵計劃難以達到對激勵對象的激勵效果。經公司董事會審慎考慮後,決定終止實施2024年限制性股票激勵計劃,並回購註銷公司2024年限制性股票激勵計劃所涉及的已授予但尚未解除限售的限制性股票1054.40萬股,同時與之配套的《2024年限制性股票激勵計劃實施考覈管理辦法》等相關文件一併終止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.